Results of the first survey for the current status of inflammatory bowel disease management in Asian countries China, and Japan, 8 but other Asian countries frequently used the "European Crohn's and Colitis Organisation" (ECCO) guidelines. For clinical assessment of disease activity of UC, most physicians used the Mayo Scoring System except Chinese physicians, who commonly used the Truelove and Witts severity index score. The CD activity index was overwhelmingly chosen for the clinical assessment of CD activity by physicians from all Asian countries. For small bowel evaluation in CD, there was a wide range of variation among countries. Physicians from Korea and China predominantly performed CT enterography, whereas those from Japan and other countries preferred small bowel follow through or balloon-assisted enteroscopy. For evaluation of perianal lesions, pelvic MRI was the most commonly used examination in all Asian countries. Across all Asian countries, over 20% of patients were given anti-tuberculosis treatment before CD diagnosis, reflecting the difficulty in discriminating between CD and intestinal tuberculosis, especially in the small bowel. 9 Nakase et al. 3 investigated IBD treatment protocols throughout Asia and showed that clinical management of IBD patients varied among Asian countries. For example, the frequency of use of certain drugs for IBD treatment such as budesonide and tacrolimus differed among Asian countries, and induction therapies for mild to moderate inflammatory small bowel CD also differed. However, common therapeutic strategies for refractory IBD and active UC were employed throughout Asian countries. Treatment strategies for steroid-refractory acute severe UC were as follows: after initially using intravenous steroids for 5-7 days, most Asian physicians with the exception of those in Japan selected anti-TNF agents, followed by cyclosporine. Many Japanese physicians favored tacrolimus, followed by anti-TNF agents, while a few Japanese physicians selected apheresis therapies. This result suggests there may be differences in available medical treatments among Asian countries. More than half of physicians in Korea, China, and Japan always tested for cytomegalovirus infection in cases of severe UC. However, only 12% of other Asian physicians always performed this test. Treatment of severe inflammatory small bowel CD greatly differed when comparing Asian and Western countries. 10 Only 3% of Asian physicians selected budesonide, while most Asian physicians selected a combination of prednisolone and 5-ASA, followed by anti-TNF agents, nutritional therapy, and thiopurines. Many Asian physicians chose thiopurines and anti-TNF agents for the treatment of steroid-dependent or refractory CD and UC patients.
There is a need to identify risk factors for poor prognosis in Asian CD patients to establish guidelines for early use of anti-TNF therapies. In Western countries, patients with risk factors such as age <40 years at diagnosis, presence of perianal lesions, early need for steroid, severe endoscopic lesions, and the existence of an NOD2/CARD15 mutation would be recommended for early treatment with anti-TNF agents (Top-down therapy). 11 When patients become resistant to anti-TNF agent therapy, serum levels of anti-TNF agents or antibodies to infliximab or adalimumab are measured to determine subsequent therapeutic strategies such as increasing the dose of anti-TNF agents or changing to another anti-TNF agent. 12 However, most Asian physicians answered "No" when asked whether they monitored serum infliximab levels or antibodies to infliximab. Facilities for monitoring of these values were limited in Asian countries. Song et al. 4 evaluated the current status of quality of IBD care in Asian countries using a questionnaire-based survey developed by the American Gastroenterological Association entitled "an adult IBD physician performance measures set" that comprised 11 specific measures. 13 The results showed www.irjournal.org that 7 of the 11 performance measures were executed well by more than 70% of physicians in Asian countries. Tuberculosis screening before anti-TNF therapy and documentation of IBD were consistently among the highest ranked measures, whereas pneumococcal immunization and prophylaxis of venous thromboembolisms (VTEs) in hospitalized patients were the lowest ranked in all countries. These lower ranked performance measures among Asian countries were comparable to a similarly low compliance in Western countries. 14 Reasons for non-performance varied among countries, especially with regard to lower ranked performance measures. For instance, pneumococcal and influenza immunizations were considered unimportant in most Asian countries, whereas lack of time was the main reason these immunizations were not performed in Korea. This survey had limitations since relying on the memories of the physicians may not accurately reflect actual performance in each country.
These 4 articles report the results of the first survey to assess the public medical insurance system, diagnosis, treatment, and quality of care for IBD in multiple Asian countries. There is currently no guideline for the diagnosis and treatment of IBD in Asian patients. Therefore, many Asian physicians commonly use guidelines of Western countries, such as the ECCO guidelines. These articles in the current issue of Intestinal Research may be the cornerstone to establishing specific guidelines for the improved management of IBD patients in Asian countries.
